로딩 중…
지수 로딩 중…
코아스템켐온
166480· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩2,465-5.56%
2026-06-19
Price Chart
코아스템켐온+3.70%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 130.33B KRW |
| Revenue | 18.39B KRW |
| Net Income | -15.16B KRW |
| Total Assets | 105.58B KRW |
| Net Assets | 48.15B KRW |
| Employees | 376 |
| Value | |
| P/B | 2.71x |
| P/S | 7.09x |
| FCF Yield | -12.22% |
| Profitability | |
| ROE | -31.50% |
| ROA | -14.36% |
| Op. Margin | -37.79% |
| Revenue Growth | -28.96% |
| Earnings Growth | -356.62% |
| Financial Health | |
| Debt Ratio | 219.29% |
| Total Debt | 36.56B KRW |
| FCF | -15.92B KRW |
| Cash | 2.76B KRW |
| Current Ratio | 0.28x |
| Performance | |
| 1Y Return | 3.70% |
| 1M Return | -32.74% |
| From 52W High | -59.59% |
| 1Y MDD | -65.98% |
| Trading | |
| Volume | 299,752 shares |
| Foreign Own. | 2.04% |
| Per Share | |
| EPS | -729 KRW |
| BPS | 1,005 KRW |
Company Info
Established in 2003 and listed on KOSDAQ in 2015, Corestem ChemOn merged with Kellun Co., Ltd., a top-three domestic non-clinical Contract Research Organization, in 2022. The company specializes in the production and sale of treatments for rare and intractable diseases based on stem cell technology, successfully commercializing stem cell therapies since 2015. It collaborates with clinical centers to develop and rapidly commercialize cell therapies, aiming to become a global leader through overseas license-out agreements and expanded indications. Corestem ChemOn is headquartered in Seongnam-si, Gyeonggi-do.